The majority of colorectal cancers begin as benign growths in the lining of the large bowel wall called adenomatous polyps. Over the years (at least ten years), these polyps grow in size and number, thereby increasing the risk that the cells in the polyps will become cancerous and invade the wall and move on to other organs. Approximately two thirds of these cancers are found in the large intestine and one third in the rectum. Early removal of these growths will prevent colorectal cancer from developing in the first place. Hence, identification and removal of polyps are key to preventing the development of colorectal cancer. Screening for colorectal cancer allows for the early detection of cancer when it is highly curable, as well as the detection of growths (polyps) that might eventually become cancer. Currently, two types of FOBT are approved by the Food and Drug Administration (FDA) to screen for colorectal cancer: guaiac FOBT (gFOBT) and the fecal immunochemical (or immunohistochemical) test (FIT, also known as iFOBT).
The global in vitro colorectal cancer testing market report provides market size (Revenue US$ Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global in vitro colorectal cancer testing market segmentation is based on test types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests , Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx).
The global in vitro colorectal cancer testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. The global in vitro colorectal cancer testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global in vitro colorectal cancer testing market and included in this report are Abbott Molecular, Inc., Alere, Inc, Beckman Coulter, Inc., BioTime, Inc., Epigenomics AG, Quest Diagnostics, Exact Sciences Corporation, Novigenix SA, CML Healthcare, Inc., and Sysmex Corporation.